In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.
Lab tests were performed under contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) in the U.S. The results have been encouraging. This could be the first natural medicine for treatment of swine flu.
This development was announced by Tasmanian scientist Helen Fitton yesterday. “With swine flu already becoming resistant to some other antiviral agents, we believe that the extract - known as Maritech 926 - offers a potent, natural alternative which supports the immune system against viral attacks,” Dr Fitton said.
The procedure of preparation could be difficult. It is taking 200Kgs of undaria seaweed to produce 1 kg of the powdered drug. Although this compound was being researched for the past eight years by biotechnology company Marinova, based at Cambridge, it is only last December that its efficacy against H1N1 flu is proven says Dr. Fitton. “In December new results found that it prevents the H1N1 virus from entering the cell and multiplying…Once you reach the effective concentration the virus is unable to enter cells - and only millionths of a gram (of Maritech 926) is needed to be effective as an inhibitor to H1N1…This ingredient is ready now to be incorporated into a product to prevent H1N1 from entering your body…The compound protects the seaweed itself from marine toxins and pathogens and similarly protects against the type of viruses that affect human cells…It has also shown very good antiviral activities against a range of influenza strains, HIV and herpes.”
According to Marinova managing director Paul Garrott the product is environmentally as well as commercially sustainable now. The next step would be to manufacture in a large scale. He hopes human trials will commence soon. He expressed hope that this could find use in other pharmaceutical and medical devices. “It is ready to go. The commercial potential is enormous in nutritional supplements, hand washes and nasal delivery products which target the spread and prevention of viral conditions…We believe that this is the only natural certified organic substance that has this level to inhibit swine flu…It is not a substitute for the swine flu vaccination, rather it is a first defense against swine flu…It is conceivable that there could be a product on the market within months,” he said.
Dr. Fitton agreed that there was a growing market for naturally derived products. She added that this product was stable, water soluble and has an extended shelf life that makes it suitable for inclusion in a wide range of delivery systems, like hand wash. The company has already applied for a patent.
Promising influenza drug candidate shows activity against resistant variants